No abstract

No abstract

Background and Aims: Levobupivacaine is relatively new drug and studies in supraclavicular blocks are limited. Our Primary aim was to evaluate and compare block characteristics and post operative analgesia of Levobupivacaine with Ropivacaine in supraclavicular block. Secondary aim was to compare systemic toxicity profiles of both drugs. Materials and Methods: Totally 60 adult patients were randomly allocated to two equal groups (n = 30). Patients in Group-R received 20 ml 0.5% ropivacaine and Group-L received 20 ml 0.5% Levobupivacaine in ultrasonography guided supraclavicular block. The main objective was to evaluate block characteristics and the duration of analgesia and other were hemodynamic variables, sedation score, and adverse effects. The data were interpreted with the help of t-test and Chi-square test. Results: Onset time, Peak effect time and total duration of sensory block was 90.33± 35.43 sec, 379.67 ± 201.21sec and 428.5± 94.19 min in Group L while it was 192.33± 65.21 sec, 484± 202.05 sec and 345.17± 104.59 min in Group-R respectively. (P value < 0.05). Onset time and total duration of motor block was 265.67 ± 117.9 sec and 331 ± 93.13 min. in Group L while it is 283.± 122.73 sec and 310± 99.83 min in Group R (p ≥ .05) The duration of post-operative analgesia was 12±2.12 hr in group L and 7.7±1.9 hr. in group R (p value < .001). Conclusion: Levobupivacaine (0.5% 20 ml) can be safely and effectively used in ultrasound guided supraclavicular block and it has early onset with prolonged duration of anaesthesia as well as prolonged post-operative pain relief compare to Ropivacaine.

Background and Aims: There is no fix and ideal dose is known for dexmedetomidine as an adjuvant in brachial plexus block. So this study was performed to evaluate different doses of dexmedetomidine added to 0.5% ropivacaine, with the primary outcome of the duration of analgesia. Secondary outcomes included the effect on block characteristics, sedation, hemodynamics and adverse effects. Materials and Methods: Totally 60 adult patients were randomly allocated to two equal groups (n = 30) using computer generated randomization. Patients in Group RD50 received 24 ml 0.5% ropivacaine + 50 µg of dexmedetomidine and Group RD100 received 24 ml 0.5% ropivacaine + 100 µg of dexmedetomidine in ultrasonography guided supraclavicular block. The primary aim was the duration of analgesia and secondary aim were onset and duration of the sensorimotor blockade, hemodynamic variables, sedation score, and adverse effects The data were interpreted with the help of t-test and Chi-square test. Results: In group RD50, the onset of both sensory and motor block was 8.18 ± 1.49 min and 14.11 ± 2.09 min, respectively, while in group RD100 it was 8.23 ± 1.41 min and 14.06 ± 2.44 min, respectively. The duration of analgesia was similar in both groups (862.32 ± 45.51 vs. 864.43 ± 44.02 min; P >.05). The occurrence of bradycardia was observed significantly greater in RD100 group patients. Conclusion:The addition of 100 µg dexmedetomidine to ropivacaine has similar effects on block characteristics and duration analgesia with a higher incidence of bradycardia as compare to 50 µg.

No abstract